Alexandria Hammond
Stock Analyst at B of A Securities
(3.37)
# 1,026
Out of 5,111 analysts
12
Total ratings
70%
Success rate
13.92%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alexandria Hammond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Upgrades: Neutral | $266 → $445 | $571.44 | -22.13% | 2 | Nov 3, 2025 | |
| REGN Regeneron Pharmaceuticals | Initiates: Outperform | $1,150 | $741.29 | +55.13% | 1 | Nov 15, 2024 | |
| PFE Pfizer | Initiates: Underperform | $25 | $25.85 | -3.29% | 1 | Nov 15, 2024 | |
| MRNA Moderna | Initiates: Underperform | $40 | $29.46 | +35.78% | 1 | Nov 15, 2024 | |
| MRK Merck & Co. | Initiates: Peer Perform | n/a | $100.30 | - | 1 | Nov 15, 2024 | |
| LLY Eli Lilly and Company | Initiates: Outperform | $1,000 | $1,027.51 | -2.68% | 1 | Nov 15, 2024 | |
| JNJ Johnson & Johnson | Initiates: Outperform | $190 | $211.58 | -10.20% | 1 | Nov 15, 2024 | |
| GILD Gilead Sciences | Initiates: Outperform | $110 | $120.40 | -8.64% | 1 | Nov 15, 2024 | |
| BMY Bristol-Myers Squibb Company | Initiates: Peer Perform | n/a | $52.41 | - | 1 | Nov 15, 2024 | |
| BIIB Biogen | Initiates: Peer Perform | n/a | $174.10 | - | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $205 | $223.32 | -8.20% | 1 | Nov 15, 2024 |
Madrigal Pharmaceuticals
Nov 3, 2025
Upgrades: Neutral
Price Target: $266 → $445
Current: $571.44
Upside: -22.13%
Regeneron Pharmaceuticals
Nov 15, 2024
Initiates: Outperform
Price Target: $1,150
Current: $741.29
Upside: +55.13%
Pfizer
Nov 15, 2024
Initiates: Underperform
Price Target: $25
Current: $25.85
Upside: -3.29%
Moderna
Nov 15, 2024
Initiates: Underperform
Price Target: $40
Current: $29.46
Upside: +35.78%
Merck & Co.
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $100.30
Upside: -
Eli Lilly and Company
Nov 15, 2024
Initiates: Outperform
Price Target: $1,000
Current: $1,027.51
Upside: -2.68%
Johnson & Johnson
Nov 15, 2024
Initiates: Outperform
Price Target: $190
Current: $211.58
Upside: -10.20%
Gilead Sciences
Nov 15, 2024
Initiates: Outperform
Price Target: $110
Current: $120.40
Upside: -8.64%
Bristol-Myers Squibb Company
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $52.41
Upside: -
Biogen
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $174.10
Upside: -
Nov 15, 2024
Initiates: Outperform
Price Target: $205
Current: $223.32
Upside: -8.20%